Susquehanna Bancshares Lowers Chemours (CC) Price Target to $44.00

Chemours (NYSE:CC) had its target price lowered by Susquehanna Bancshares from $65.00 to $44.00 in a research note issued on Monday, The Fly reports. The firm currently has a “positive” rating on the specialty chemicals company’s stock. Susquehanna Bancshares’ price objective points to a potential upside of 31.03% from the company’s current price.

A number of other analysts have also recently issued reports on the company. ValuEngine cut Chemours from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 2nd. Morgan Stanley cut their price objective on Chemours from $48.00 to $47.00 and set a “hold” rating for the company in a research report on Tuesday, September 25th. Zacks Investment Research cut Chemours from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 11th. Citigroup cut their price objective on Chemours from $61.00 to $44.00 and set a “buy” rating for the company in a research report on Thursday, October 11th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating on shares of Chemours in a research report on Thursday, September 13th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $53.60.

Shares of NYSE CC opened at $33.58 on Monday. Chemours has a 52 week low of $31.34 and a 52 week high of $54.62. The company has a quick ratio of 1.39, a current ratio of 2.03 and a debt-to-equity ratio of 3.48. The company has a market cap of $6.08 billion, a P/E ratio of 8.79, a P/E/G ratio of 0.39 and a beta of 2.74.

Chemours (NYSE:CC) last issued its quarterly earnings results on Thursday, November 1st. The specialty chemicals company reported $1.49 EPS for the quarter, beating the consensus estimate of $1.42 by $0.07. Chemours had a return on equity of 106.98% and a net margin of 16.02%. The firm had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.71 billion. During the same period in the prior year, the firm posted $1.12 earnings per share. The business’s quarterly revenue was up 2.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Chemours will post 5.7 EPS for the current year.

A number of institutional investors have recently bought and sold shares of the business. Trilogy Capital Inc. acquired a new stake in shares of Chemours in the 3rd quarter valued at $179,000. Gofen & Glossberg LLC IL acquired a new stake in shares of Chemours in the 2nd quarter valued at $204,000. Gideon Capital Advisors Inc. acquired a new stake in shares of Chemours in the 2nd quarter valued at $209,000. Signition LP acquired a new stake in shares of Chemours in the 3rd quarter valued at $232,000. Finally, Quantitative Systematic Strategies LLC acquired a new stake in shares of Chemours in the 2nd quarter valued at $247,000. Hedge funds and other institutional investors own 76.33% of the company’s stock.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.

Featured Story: How much money do you need to begin day trading?

The Fly

Analyst Recommendations for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply